Viewing Study NCT06562816



Ignite Creation Date: 2024-10-26 @ 3:38 PM
Last Modification Date: 2024-10-26 @ 3:38 PM
Study NCT ID: NCT06562816
Status: RECRUITING
Last Update Posted: None
First Post: 2024-08-16

Brief Title: Comparing Trypsin-Chymotrypsin and Naproxen Sodium for Post-endodontic Treatment Pain A Randomized Controlled Trial
Sponsor: None
Organization: None

Study Overview

Official Title: Comparing Trypsin-Chymotrypsin and Naproxen Sodium for Post-endodontic Treatment Pain A Randomized Controlled Trial
Status: RECRUITING
Status Verified Date: 2024-08
Last Known Status: None
Delayed Posting: No
If Stopped, Why?: Not Stopped
Has Expanded Access: No
If Expanded Access, NCT#: N/A
Has Expanded Access, NCT# Status: N/A
Acronym: None
Brief Summary: This study aims to compare the pain reduction efficacy of Trypsin-Chymotrypsin and Naproxen sodium after root canal treatment in patients with symptomatic irreversible pulpitis A lot of patients suffer greatly from post endodontic treatment pain and have a fear of dental treatments due to the pain Patients refuse to go to the dentists and neglect oral hygiene care Thats why it is very important to find an effective drug regimen to reduce this post treatment pain The null hypothesis is that there will be no difference between the efficacy and mean pain scores of Trypsin-chymotrypsin and Naproxen Sodium for post-endodontic treatment pain Conducted as a triple-blinded parallel randomized controlled trial 100 patients will be randomly assigned to receive either Trypsin-Chymotrypsin or Naproxen sodium following standard root canal therapy Pain levels will be assessed using a numerical rating scale at 1 6 12 and 24 hours post-treatment to evaluate the effectiveness of these two pain management modalities
Detailed Description: i Background Prevention or management of pain especially after root canal treatment is of utmost importance to Endodontists Non-steroidal anti-inflammatory drugs NSAIDs have been the most commonly used pain reduction modality in cases of irreversible pulpitis but they do come with certain demerits A lot of other alternatives have been researched as better alternatives for NSAIDs Trypsin- Chymotrypsin has been proven to be an effective pain reducer after endodontic therapy

ii Objective The objective of this study is to compare the pain reduction efficacy of Trypsin- Chymotrypsin and Naproxen sodium after root canal treatment

iii Methodology In this triple-blinded parallel randomized controlled trial a total of 100 patients will be included who are coming to the Operative Dentistry department for root canal treatment for any tooth The patient must have a history of symptomatic irreversible pulpitis The patients will be randomly allocated into two groups One group n 50 will be the Trypsin- Chymotrypsin group and the second group n 50 will be the Naproxen sodium group active control group The root canal treatment will be performed as usual The first group will receive Trypsin- Chymotrypsin 1100000 and the second group will receive Naproxen Sodium 550mg in sealed envelopes The intensity of post-operative pain will be evaluated using a numerical rating scale at 1 hour 6 hours 12 hours and 24 hour intervals

iv Sequence Generation Computer generated randomization using appropriate software randomorg to assign the participants to trypsin-chymotrypsin or naproxen sodium group ensuring a complete random allocation to each treatment arm decreasing a risk of bias and enhancing the internal validity of the study

v Blinding The participants researcher and outcome assessors will be blinded in this research triple blinded

vi Allocation Concealment The allocation concealment will be achieved by packaging medicines in tightly sealed opaque envelopes by a different person not conducting research or assessing outcomes This process ensured that researchers involved in participant enrollment could not predict or influence the treatment assignment reducing the risk of selection bias

Study Oversight

Has Oversight DMC: None
Is a FDA Regulated Drug?: None
Is a FDA Regulated Device?: None
Is an Unapproved Device?: None
Is a PPSD?: None
Is a US Export?: None
Is an FDA AA801 Violation?: None